President & CEO, Founder
Russ co-founded SentreHEART in 2005, and has extensive experience with product development, global product launches and driving adoption of new technologies. He was the VP of Sales and Marketing for Artemis Medical, where he played a vital role in its 2004 sale to Johnson & Johnson. Before that, he was VP of Marketing at Heartport, which was acquired by Johnson & Johnson in 2001.
Previously, he held a variety of sales, marketing and operational positions of increasing responsibility at Boston Scientific. Russ began his career at Procter & Gamble, where he progressed through a range of sales and marketing roles. He holds a BS in finance from the University of Florida.
Chief Financial Officer
Chris has served as our CFO since 2015. Previously, he served as interim CEO and interim CFO at Hansen Medical, where he has served as a Director since 2006. He also served as CFO for Anthera Pharmaceuticals, Inc., a drug development company, from 2007 to 2013, and additionally served as its Chief Business Officer from 2011 to 2013.
Chris previously held C-level positions at Asthmatx, Inc., a medical device company acquired by Boston Scientific, and at Peninsula Pharmaceuticals, Inc., until its acquisition by Johnson & Johnson in June 2005. He holds a B.S. from California Polytechnic State University, San Luis Obispo, and an M.B.A. from Saint Mary’s University, Texas.
Vice President of Operations
Joining SentreHEART in November 2008 as VP of Operations, Bob has been responsible for bringing the company’s closure technology from development to commercial readiness. He previously served as Director of New Product Development for Cordis (Johnson & Johnson) from 2003–2008, where he led their peripheral drug-eluting stent program. From 1990–2002, Bob held positions of increasing responsibility with Boston Scientific’s Scimed and Medi-Tech, including seven years as VP of Operations, managing plants in both Boston and Miami through numerous product scale-up and transfer initiatives, and overseeing all manufacturing operations. He was Process Engineering Manager with C.R. Bard from 1986-1990. Originally from the Chicago area, Bob earned his BS in biochemistry from the University of Minnesota.
Vice President of Clinical Affairs
Pam joined SentreHEART in 2014 and brings 25 years of experience in the medical device industry. She previously served as VP of Clinical Affairs at Mardil Medical, a privately held, early-stage company developing implantable medical devices designed for treating structural heart disease and related conditions. Before that, she was VP of Clinical Affairs for St. Jude Medical’s Cardiovascular and Ablation Technologies division as well as VP of Clinical and Regulatory Affairs for St. Jude’s AGA Medical. With a clinical development portfolio that spanned the enterprise’s vascular and structural heart product offerings (>$5 billion market), she served as primary clinical leader for all global pre- and post-market clinical programs, interfacing with FDA and worldwide regulators. She has also held clinical leadership positions at Boston Scientific, Update Medical, First Circle Medical, Heart Technology and SciMed Life Systems. Pam earned her BS in radiologic sciences from the University of North Carolina at Chapel Hill, and advanced certifications from Wake Forest University Medical Center in interventional cardiovascular and peripheral therapeutic applications. Additionally, she is a graduate of the Executive Education program at Columbia Business School.
Vice President of Research & Development
After joining SentreHEART in June 2007, Greg became Director of R&D in June 2008. Since then, he has developed and introduced the six components of SentreHEART’s LAA closure system for commercialization. Greg was previously an R&D engineer at FoxHollow Technologies, where he managed and led projects for improvements to the small-vessel plaque excision device platform until it was acquired by ev3, Inc. in 2007.
From 1998–2005, he held several process and product development engineering positions at Guidant Corporation, working on peripheral vascular products. He earned his BS in biosystems engineering from the University of California at Davis and his MS in engineering management from Santa Clara University.
BOARD OF DIRECTORS
Casey Tansey & Phil Young
Russell Hirsch, M.D., PhD
Chen Yu, MD
Andrew ElBardissi, MD
Russell A. Seiber
President & CEO, Founder
Richard M. Ferrari